藥明康德(02359.HK)斥1,500萬美元認購私募基金份額
藥明康德(02359.HK)(603259.SH)公佈,全資子企業WuXi PharmaTech Healthcare Fund I L.P於昨日(27日)與私募基金普通合夥人及管理公司簽署合夥協議,將認繳投資基金Longwood Fund VI, L.P.的1,500萬美元份額,約佔已募集投資基金份額的19.16%。
該投資基金主要專注於投資北美洲和英國的藥物、治療方法及相關領域的創新生物技術企業,未來計劃投資10至12個項目。公司表示,本次投資有助於公司在獲取投資收益的同時,通過美國本土的知名醫療健康風險投資機構的行業網絡,瞭解北美洲和英國產業前沿動態,深度挖掘當地優質生物科技和醫療健康企業的潛在投資機會,並協助業務部門與潛在客戶建立密切合作關係,進一步深化拓展一體化醫藥研發平臺能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.